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Abstract. It is well known that glucocorticoids and mineralocorticoids are part of the list of hormones that control adipogenesis
as well as diﬀerent aspects of the physiology of the adipose tissue. Their actions are mediated through their binding to the
glucocorticoid and the mineralocorticoid receptors (GR and MR, respectively), in complex with heat shock proteins (Hsps) and
high molecular weight immunophilins (IMMs). Albeit many aspects of the molecular mechanism of the corticosteroid receptors
are not fully elucidated yet, it was not until recently that the ﬁrst evidences of the functional importance of Hsps and IMMs in
the process of adipocyte diﬀerentiation have been described. Hsp90 and the high molecular weight IMM FKBP51 modulate GR
and MR activity at multiple levels, that is, hormone binding aﬃnity, their subcellular distribution, and the transcriptional status,
among other aspects of the NR function. Interestingly, it has recently been described that Hsp90 and FKBP51 also participate in
the control of PPAR𝛾 , a key transcription factor in the control of adipogenesis and the maintenance of the adipocyte phenotype.
In addition, novel roles have been uncovered for FKBP51 in the organization of the nuclear architecture through its participation
in the reorganization of the nuclear lamina and the control of the subnuclear distribution of GR. Thus, the aim of this review is
to integrate and discuss the actual understanding of the role of corticosteroid receptors, their chaperones and cochaperones, in the
process of adipocyte diﬀerentiation.
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1. Introduction
The pandemic of obesity has brought attention on adipose
tissue and the development of fat cells. Undoubtedly, adi-
pose tissue plays a central role in the control of energy
balance and lipid homeostasis; however, during the last two
decades it has been demonstrated that adipocytes release
a variety of factors, including cytokines, chemokines, and
many other biologically active molecules, generically called
adipokines that made adipose tissue be regarded as an
active endocrine organ [1]. Adipokines signal organs of
metabolic importance including brain, liver, skeletal muscle,
and the immune system [2, 3]. These functions appear to
be modulated by the location of the adipose tissue (visceral
vs. subcutaneous vs. bone marrow adipose) [4, 5], by the
size of the average adipocyte in the tissue [6], by the
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cross-talk between adipocytes and other cell types present
in this tissue like macrophages [7, 8], and by adipocyte
metabolism of glucose [9] and corticosteroids [10]. In this
way, adipose tissue has a central role modulating lipid
and glucose metabolism homeostasis, blood pressure, and
inﬂammation; in other words, it is a master regulator of the
metabolic homeostasis of the organism. In obese individuals,
the secretion of adipokines is deregulated [1] and adipose
tissue is generally hypertrophic and inﬁltrated by a higher
number of macrophages compared to normal tissue [7],
events that correlate with measures of adiposity and insulin
resistance [11, 12]. This leads to the establishment of a
state of chronic inﬂammation leading to metabolic disease
[13]. However, a very recent report shows that up to
certain level proinﬂammatory signaling is necessary in the
adipocyte for the adequate remodeling and expansion of the
adipose tissue [14]. Failure of the normal proinﬂammatory
response leads to increased ectopic lipid accumulation due to
deﬁcient adipogenesis, accompanied by glucose intolerance
and systemic inﬂammation, demonstrating that adequate
control of adipose tissue inﬂammatory signaling facilitates
the appropriate storage of excess nutrients maintaining the
metabolic equilibrium [14].
Conversely, lipodystrophy, a disorder characterized by
selective total or partial loss of body fat, is also accompanied
by similar metabolic consequences as obesity, including
insulin resistance, dyslipidemia, hepatic and myocellular
steatosis, and increased risk for diabetes and atherosclerosis
[15, 16], reinforcing the notion of the key role of adipose
tissue in the control of the homeostasis of body metabolism.
Taking into consideration what has been mentioned, it
is relevant to uncover the factors that control not only
adipogenesis but also those that exert control in the function
of the adipose cell itself. It is well known that corticosteroids
are key regulators not only of fat distribution, but also of
adipocyte diﬀerentiation as demonstrated both in vitro and in
vivo [17–21] and are required for the induction of lipogenic
genes and lipolisis in adipocytes [22, 23] as well as for
restraining of adipose tissue inﬂammation in obesity [24].
Corticosteroids exert their action through the binding
to their cognate receptors, the glucocorticoid and miner-
alocorticoid receptor (GR and MR, respectively), that are
present in the cytoplasm. For proper steroid hormone action,
GR and MR need to be part of an heterocomplex with
the 90-kDa and 70-kDa heat shock proteins, Hsp90 and
Hsp70, respectively, the acidic protein p23, and a protein
that belongs to the conserved and a large family known as
immunophilins (IMMs) [25, 26]. Among the members of the
IMMs family, FK506 binding protein (FKBP)52, FKBP51,
Cyclophilin (CyP) 40, and three IMM-like proteins, protein
phosphatase 5 (PP5), hepatitis virus B X-associated protein 2
/AhR-associated protein 9 (XAP2/ARA9), and WAF-1/CIP1
stabilizing protein (WISp) 39, have been recovered to date
in steroid receptor Hsp90 complexes [25, 27]. Detailed
revisions have been made on the roles of glucocorticoids
and mineralocorticoids actions in adipose tissue biology
[28, 29]; thus our aim will be to summarize the molecu-
lar mechanism of action of gluco- and mineralocorticoids
and then discuss recent ﬁndings of how chaperones and
cochaperones not only regulate GR and MR at diﬀerent
levels but also exert new roles in the process of adipogen-
esis.
2. Glucocorticoids Actions in the Adipose Tis-
sue
Glucocorticoids are required for proper adipocyte diﬀeren-
tiation [17, 30, 31] and have a wide spectrum of actions
on adipose tissue biology; for a recent review refer to [28].
As already mentioned, they exert their action through their
binding to the GR that is present in the cytoplasm as part
of a heterocomplex with Hsp90, Hsp70, p23, and the high
molecular weight immunophilin FKBP51 or FKBP52. GR
mRNA [32] and protein [33] exhibit a particular pattern
of expression, with higher levels during the ﬁrst several
hours after induction of the adipogenic program of 3T3-
L1 preadipocytes, followed by a period of lower level of
expression that gradually increases back to preadipocytes
level after several days. There is still some controversy about
GR requirement for proper adipogenesis to occur. It has been
reported that knock-down of GR by speciﬁc siRNA blocks
the diﬀerentiation of 3T3-L1 preadipocytes [34] but another
report provides some evidence that this is not the case [21].
However the role of GR appears to be more complex, based
on the fact that it has been shown that brown adipose cell
lines generated from newborn homozygous GR-knockout
mice showed mildly impaired adipocyte diﬀerentiation with
a decrease of lipid accumulation mainly at early time points
compared to wild-type adipocytes [35]. Thus, diﬀerences in
cell lines and/or cell sourcesmay account for diﬀerent results,
and more studies are needed to shed light on this complex
issue.
There is no doubt that glucocorticoids have a proadi-
pogenic eﬀect that is evident in the development of central
obesity in patients with high levels of circulating glucocorti-
coids, as observed in Cushing’s syndrome or in patients that
required prolonged administration of this steroid hormone
therapeutically [28, 36]. Further, adipose tissue-dependent
ampliﬁcation of glucocorticoid production in transgenic
mice results in a full metabolic syndrome, including central
obesity, insulin resistance, and hypertension [10]. In contrast,
glucocorticoid inactivation is associated with resistance to
metabolic dysfunction [37, 38].
3. Mineralocorticoids Actions in the Adipose
Tissue
Aldosterone and its cognate receptor MR besides controlling
water and salt homeostasis are also involved in the complex
biology of the adipocytes [29]. Many reports have shown
that aldosterone is required for proper adipogenesis [20,
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21]. 3T3-L1 preadipocyte diﬀerentiation is blocked in the
presence of aldosterone antagonists such as ZK91587 [20],
spironolactone [21], or drospirenone [39]. Further, knock-
down ofMR by siRNAsmarkedly inhibited 3T3-L1 cells dif-
ferentiation [21]. Taken together, these studies demonstrate
the importance of aldosterone/MR in the adipogenic process.
Signiﬁcantly higher MR mRNA levels are present in white
adipose tissue (WAT) of obese ob/ob and db/db mice than in
lean control mice [40]. Treatment of ob/ob and db/db obese
mice with eplerenone, a selective MR antagonist, does not
result in signiﬁcant changes in body weight; however, this
treatment reduces the number of hypertrophic adipocytes,
decreases the inﬁltration of adipose tissue by macrophages,
and corrects glucose tolerance test [40]. Therefore, MR may
play a key role in the development of the metabolic syndrome
and its blockade could be beneﬁcial for obese patients who
suﬀer insulin resistance and type 2 diabetes.
Interestingly, several reports, some of them even pub-
lished when no role was known for aldosterone in adipogene-
sis, indicated an association between high serum aldosterone
levels and obesity [41–46]. In this regard, secretory products
isolated from human adipocytes strongly stimulate steroido-
genesis in adrenocortical cells with a predominant eﬀect
on mineralocorticoid secretion [47]; the identity of these
products still remains elusive. Further, visceral adipocytes
isolated from SHR/NDmcr-cp, a rat model of metabolic
syndrome, secrete factors that stimulate aldosterone produc-
tion in adrenocortical cells, activity that was not detected in
adipocytes from non-obese SHR [48]. The stimulatory eﬀect
of adipocyte-conditioned medium on aldosterone secretion is
independent of adipose angiotensin II since the eﬀect is not
blocked in the presence of antagonists of angiotensin type 1
receptor [47, 48].
Importantly, the adipocyte itself is another source of both
aldosterone synthesis and secretion [49, 50]. Preadipocytes
as well as adipocytes express CYP11B2 (aldosterone syn-
thase) gene and have a functionally active aldosterone
synthase, making these cells aldosterone-producing cells
[50]. Speciﬁc inhibition of CYP11B2 interferes in the normal
process of adipogenesis [50]. It remains to be investigated
whether local synthesis of aldosterone may depend on
fat depot and whether changes in the local aldosterone
production in the hypertrophic adipocyte may also contribute
to the pathophysiology of obesity.
Healthy adipose tissue around small arteries secretes
factors that inﬂuence vasodilation by adiponectin-dependent
increase in nitric oxide bioavailability [51]. In perivascu-
lar fat from obese subjects with metabolic syndrome this
dilator eﬀect is lost possibly due to defects of hyper-
trophic adipocytes to properly secrete adiponectin [51].
However, adipose local production of aldosterone may
also exert a paracrine action modulating the microvascular
tone. Small arteries from db/db mice exhibit endothelial
dysfunction [52], and acetylcholine-induced relaxation of
mesenteric arteries is improved by pretreatment of db/db
mice with eplerenone [50]. Thus, local aldosterone secreted
by perivascular adipocytes may contribute to endothelial
cells dysfunction, explaining the beneﬁcial eﬀect of the
selective MR antagonist eplerenone on the microvasculature
[50].
4. Do Glucocorticoids and Mineralocorticoids
Exert Coordinated Actions in Adipose Tis-
sue?
Glucocorticoids and mineralocorticoids have their own cog-
nate receptors; however, the way they exert their biological
actions is more complex. Circulating levels of aldosterone
are 100 to 1000 times lower than cortisol which can bind
to MR with 10-fold higher aﬃnity than to GR [53]. In
order to control GR/MR activation by glucocorticoids, 11-
beta hydroxysteroid dehydrogenases (11𝛽-HSDs) types 1 and
2 determine the availability of intracellular concentrations
of active glucocorticoids [54, 55]. 11𝛽-HSD1 is expressed
primarily in glucocorticoid-target tissues, such as liver, the
central nervous system, and the adipose tissue, and acts as a
predominant 11𝛽-reductase NADP(H) dependent that ampli-
ﬁes glucocorticoid action. On the other hand, 11𝛽-HSD2
is a high aﬃnity NAD-dependent dehydrogenase expressed
primarily in mineralocorticoid target tissues, such as kidney,
and metabolizes glucocorticoids to their 11-dehydro deriva-
tives, that is, cortisone, 11-dehydrocorticosterone, that have
weak or no aﬃnity for MR [56, 57]. Thus, the presence of
11𝛽-HSD2 “protects” MR from its activation through the
binding of glucocorticoids. In adipose tissue, 11𝛽-HDS2,
which reduces active levels of glucocorticoids, is expressed
at much lower levels than 11𝛽-HDS1 [58–60]. In Flier´s
lab transgenic mice that expressed 11𝛽-HSD2 driven by
the adipocyte fatty acid binding protein 2 promoter were
generated. These mice have the highest levels of 11𝛽-HSD2
in adipose tissue, and when they are exposed to high-fat diet
they are resistant to weight gain, event that is associated
with decreased food intake, increased energy expenditure,
and improved insulin sensitivity [38]. Further, 11𝛽-HSD-1
null mice showed reduced visceral fat accumulation upon
high-fat feeding and expressed higher PPAR𝛾 , adiponectin
and lower resistin, and tumor necrosis factor-𝛼, pattern of
gene expression that indicates high insulin sensitivity [37].
Therefore, it is possible that high concentration of cortisol
within the adipose tissue that cannot be inactivated due to
low levels of 11𝛽-HDS2 may exert their action not only
upon GR activation but also through MR. In obese patients,
serum cortisol levels are not increased and can be even
lower than serum aldosterone levels [61, 62]; therefore
increased local activation of cortisol from cortisone observed
in obesity has detrimental consequences in adipose tissue
physiology.
The requirement of an adequate level of gluco- and
mineralocorticoids stimulus is highlighted by the fact that
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the activation of GR and MR has some opposite out-
comes in adipocytes. For example, MR activation increases
the expression of interleukin-6 and plasminogen activator
inhibitor (PAI) 1 while GR activation decreases them [35].
It has also been reported that the synthetic glucocorticoid
dexamethasone (DEXA) decreases the expression of proin-
ﬂammatory cytokines [24, 63–65] as well as macrophage
inﬁltration in adipose tissue [24]. Further, treatment of
obese diabetic db/db mice with eplerenone, a selective
MR antagonist, decreases the expression of tumor necro-
sis factor –𝛼, monocyte chemoattractant protein-1, and
macrophage protein CD69 while it increases the expression
of adiponectin and peroxisome proliferator-activated receptor
(PPAR)𝛾 in adipocytes from the retroperitoneal fat depot
[66]. Eplerenone treatment also decreases macrophage inﬁl-
tration and the generation of reactive oxygen species in
adipose tissue [40]. Since the pattern of expressed genes is
diﬀerent depending on the participation of GR or MR, the
strict control of their activation is required in the adipose
cell to achieve the proper biological response. We need to
keep in mind that in the genome there are approximately 2–
5 × 106 potential recognition elements for binding of this
nuclear receptors (NRs); however, a few thousand binding
sites are occupied [67, 68]. Therefore, how are GR and MR
speciﬁcities achieved? Several coordinate layers of GR/MR
control allow them to gain such speciﬁcity, among them
are regulation of their subcellular distribution, posttrans-
lational modiﬁcations that may modulate their interaction
with factors that control their transcriptional capacity, and
mechanisms that mediate the recognition of the response
elements in the architecture of the genome contribute to
it.
4.1. GR and MR expression during adipogenesis. In order
to gain insight in a better understanding of the NRs function
during adipogenesis, Fu et al. analyzed the gene expression
proﬁles of NRs during diﬀerentiation of murine 3T3-L1
preadipocytes. Of the forty-nine NRs analyzed, thirty are
expressed at some point during 3T3-L1 adipogenesis and
seventeen of them are expressed in a temporal-speciﬁc
manner [32]. GR and MR belong to a group of NRs that
are expressed in a biphasic manner, with higher levels of
expression during the ﬁrst several hours after induction of
the adipogenic program, followed by a period of lower level
of expression that gradually increases back to preadipocytes
levels after several days [32]. GR and MR expression are
found substantially higher in mature primary adipocytes
relative to preadipocytes [32]. In agreement with mRNA,
GR protein expression levels follow a similar pattern [33].
It was proposed that this temporal pattern of GR and
MR expression possibly marked distinct transcriptionally
regulated boundaries at early, middle, and late stages of
adipocyte diﬀerentiation [32]. In addition, GR mRNA levels
exhibit diﬀerences that depend on the fat depots. GR
mRNA is 2- to 4-fold higher in omental than subcutaneous
adipose tissue [22, 69–71]. It will be relevant to determine
whether MR expression is similar or not in diﬀerent fat
depots.
Besides diﬀerences in GR and MR levels of expression,
the existence of GR and MR isoforms has to be taken into
consideration. GR𝛼 and -𝛽 are GR isoforms generated by
alternative splicing of exon 9 [72, 73]. The resulting proteins
are identical except that GR𝛼 contains 5 additional amino
acids and GR𝛽 additional non-homologous 15 amino acids.
Both are widely expressed in all tissues with GR𝛼 being
present at relatively higher levels in themajority of the tissues
examined in humans and mice [74, 75]. GR𝛽 functions as a
dominant negative inhibitor of GR𝛼; therefore the GR𝛼/GR𝛽
ratio may also mediate diﬀerential glucocorticoid responses.
Insulin increases GR𝛽 mRNAwithout aﬀecting GR𝛼 mRNA
in mouse embryonic ﬁbroblasts [75]. Importantly, GR𝛼/GR𝛽
ratio changes in the liver when fasted mice are re-fed
indicating that the GRs ratio changes in response to insulin
[75]. To add more complexity, diﬀerent isoforms from the
GR𝛼 transcript can be generated by alternative translation
initiation mechanisms [76]. No signiﬁcant diﬀerences have
been observed in their aﬃnity for glucocorticoids or their
capacity to interact with glucocorticoid response elements
(GREs) present in GR target genes, but their subcellular
distribution shows some diﬀerences [76]. Importantly, it
has been shown that translationally generated GR𝛼 isoforms
regulate both common and distinct sets of genes in the
same cell. Lu et al. showed that, in U-2 OS cells, a human
osteoblastic sarcoma cell line that lacks endogenous GR,
expression of diﬀerent GR isoforms have distinct capabilities
to activate the cell death program [76, 77]. Since they
have identical DNA- and ligand-binding domains, it has
been proposed that this functional diﬀerence may rely
on their diﬀerential ability to recruit coregulators and/or
the recognition of chromatin modiﬁcations on target genes
[77].
MR has also isoforms and protein variants that create
diversity around one single gene [78–81]. MR is expressed as
two diﬀerent protein variants,MRA andMRB, resulting from
Kozak sequences that initiate alternative translation [82].
Thus, future studies are required to address the contribution
of GR and MR isoforms in the process of adipogenesis as
well as their expression in the diﬀerent adipose depots where
they may possibly contribute to the diﬀerential response to
corticosteroid hormones.
GR and MR undergo diﬀerent posttranslational modiﬁ-
cations that constitute another layer of control to achieve
speciﬁcity in the corticosteroids response. GR can be sub-
strate for phosphorylation [83–87], sumoylation [88–92],
ubiquitination [93, 94], and acetylation [95]. These posttrans-
lational modiﬁcations regulate the ﬁnal biological outcome
depending on GR bymodulating GR subcellular distribution,
protein stability, chromatin binding, transcriptional capacity,
and its interaction with coregulatory complexes. In the
case of MR, it has been reported that it can undergo
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phosphorylation [96–99], acetylation [100], and sumoylation
[101], having consensus sites for possible ubiquitination.
How posttranslational modiﬁcations may control hormonal
responses as well as the crosstalk of steroid hormones with
other signaling molecules in adipose tissue still remains to be
elucidated in detail.
4.2. GR and MR transformation and nuclear translocation.
For proper steroid hormone action, it is well established that
GR and MR need to be part of a heterocomplex with the
90-kDa and 70-kDa heat shock proteins, Hsp90 and Hsp70,
respectively [25, 26]. In the absence of ligand, GR and MR
reside primarily in the cytoplasm, and it has been accepted
that, upon hormone binding, they dissociate from the Hsp90
heterocomplex for their translocation to the nucleus by
free diﬀusion. However, during the last decade several
reports provided evidence that movement of GR and MR is
more complex than simple diﬀusion. It was demonstrated
that the intermediate chain of the motor protein dynein
coimmunoprecipitates with the Hsp90•FKBP52 complex of
the GR [102–104] and MR [105, 106] suggesting that this
motor protein can facilitate the retrograde movement of the
steroid receptor (Figure 1). Blockage of the Hsp90•FKBP52
or FKBP52•dynein interactions by overexpressing the tetra-
tricopeptide repeat motif (TPR) domain or the peptidyl-
prolyl isomerase domain of the IMM, respectively, slows
the rate of receptor translocation to the nucleus in a similar
manner as inhibition of the Hsp90 function by geldanamycin
treatment [107]. In all these cases, the nuclear localization
of the receptor was not fully abrogated, but it was delayed.
Therefore, GR andMR possess twomechanisms of transport,
a rapid Hsp90•FKBP52•dynein complex-dependent mecha-
nism and a slow heterocomplex-independent mechanism by
simple diﬀusion.
The classic model of GR/MR receptor activation estab-
lishes that Hsp90 “anchors” NR in the cytoplasmic compart-
ment and, upon hormone binding, the NR has to undergo
a process known as “transformation,” that corresponds to
its dissociation from Hsp90, for then translocating to the
nucleus. Since Hsp90•FKBP52 complex facilitates GR and
MR movement towards the nucleus, consequently their
transformation should not take place immediately upon
ligand binding (Figure 1). Moreover, it has been shown
that the whole MR•Hsp90-based heterocomplex can be
transiently recovered in the nucleoplasmic fraction of the
nucleus shortly after steroid hormone incubation [106, 108].
Thus, the steroid-receptor transformation could possibly take
place in the nucleus [109], raising the possibility that the
entire oligomeric structure could pass intact through the
nuclear pore for transformation to be a nuclear rather than
a cytoplasmic event (Figure 1). In this regard, GR and its
associated chaperones bind with proteins of the nuclear pore
such as nucleoporins (Nups) and importin (Imp)-𝛽, and it
has been shown that the entire Hsp90 heterocomplex cross-
linked to GR translocates intact through the nuclear pore in
digitonin-permeabilized cells [110]. There is evidence that
Imp-𝛼 is cointernalized with the GR [111], whereas Imp-𝛽
is not. Nonetheless, the knock-down of Imp-𝛽 signiﬁcantly
delayed GR nuclear import [110]. It has been reported that
many importins including Imp-𝛽 eﬀectively suppress the
aggregation of cargoes [112]. It can be envisioned that
the presence of chaperones and co-chaperones associated
to importin, Nups, and the cargo itself may prevent the
aggregation of cargoes when relatively hydrophobic domains
are exposed [109]. When these complexes are disrupted
by Hsp90 inhibitors such as radicicol or geldanamycin, the
nuclear translocation rate of GR [102, 104] and MR [105,
113] undergoes a substantial delay, in line with the idea
that importin-Nup-chaperone complexes may facilitate their
nuclear pore translocation step.
4.3. The chaperone Hsp90: does it play a role in adipo-
genesis? During the process of diﬀerentiation of 3T3-L1
preadipocytes no change is observed in the protein levels
of the chaperones and cochaperones Hsp90, Hsp70, and
p23 [33]. Hsp90 accounts for 1-2% of the total soluble
proteins in resting cells, ˜6-7 % in cancer cells, and up
to 10% in stressed cells [114–116]. Hsp90 is a molecular
chaperone that associates with numerous substrate proteins
called clients modulating their folding and function, among
them are protein kinases and transcription factors [117–
119]. In this manner, Hsp90 controls metastable proteins
that are regulatory hubs in biological networks. The master
regulator for acquisition and maintenance of the adipocyte
phenotype PPAR𝛾 has been recently incorporated to the large
list of Hsp90 client proteins. Inhibition of Hsp90 by treatment
of 3T3-L1 cells with geldanamycin or its analogs at early
time points of the adipogenic process prevented the cells to
diﬀerentiate properly [120–122]. It has been proposed that
the antiadipogenic eﬀect of geldanamycin may result from
the destabilization of PPAR𝛾 that is targeted to degradation
by the proteasome [120], to decrease PDK1-Akt activities
leading to the blockade of the mitotic clonal expansion
at the onset of adipogenesis [121], and the decrease of
GR and MR activities [122]. Hsp90 is essential for wide
spectrum of cellular processes such as protein folding, protein
degradation, and signal transduction cascades [117, 123],
having been recently shown that Hsp90 also participates in
the maintenance of RNA polymerase II pausing, function
required for the adequate gene expression when cells have
to respond to environmental stimuli [124]. Therefore the
blockade of the adipogenic program upon Hsp90 inhibition
could be the result of more widely disruption of signaling
pathways as well as nuclear events depending on Hsp90
surveillance.
4.4. High molecular weight immunophilins: regulatory func-
tions beyond NR control. IMMs comprise a family of
proteins classiﬁed by their ability to bind immunosuppressant
drugs in which cyclophilins bind cyclosporine A whereas
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Figure 1:Model of GR and MR action: the adipogenic media contain DEXA, IBMX, and insulin and are supplemented with fetal bovine
serum. Upon corticosteroid hormone binding to its receptor (GR or MR) FKBP51 is exchanged for FKBP52 that facilitates the retrograde
movement of the NR towards the nucleus. IBMX increases cAMP leading to PKA activation that triggers the translocation of FKBP51 from
mitochondria to the nucleus, possibly upon changes in its phosphorylation status. In the nucleus GR binds to its target genes, localizing in
the NL (nuclear lamina) and possibly in the NM (nuclear matrix). FKBP51 is retained in the nucleus by its interaction with the NL, the NM,
and chromatin, regulating GR-target genes and possibly other genes.
FKBPs bind FK506. The high molecular weight IMMs
FKBP51 and FKBP52 do not play a role in immunosup-
pression and rather have been related to steroid receptor
regulation [125]. The FKBPs are modular proteins that
possess FKBP12-like peptidyl-prolyl isomerase (PPIase)
domains 1 and 2 (FK1 and FK2) and a tetratricopeptide
repeat motif (TPR). The FK1 domain is required for the
binding of the immunosuppressive drug FK506, it confers
PPIase activity, and it is also the primary domain required
for steroid hormone receptor regulation [125–127]. The TPR
domain contains sequences of 34 amino acids repeated
in tandem through which FKBPs interact with Hsp90.
FKBP51 and FKBP52 share 60% identity and 70% similarity;
however, the former has been so far mainly reported to
be a negative regulator of steroid hormone receptors while
the latter is a positive one [103–105, 125, 127]. When
diﬀerentiation of 3T3-L1 preadipocytes is induced, it was
reported that FKBP51 has a transient expression at very
early time points (day1 up to day 4 of diﬀerentiation)
and then its expression decreases to undetectable protein
levels [128]. More recent studies demonstrate that FKBP51
and FKBP52 exhibit opposite changes in their level of
expression during the process of adipocyte diﬀerentia-
tion. FKBP51 expression progressively increases whereas
FKBP52 decreases as adipogenesis progresses [33, 129].
The diﬀerences observed between early and recent studies
may possibly depend on the development of highly sensitive
and speciﬁc antibodies now available for the study of
these IMMs. Further, the changes in FKBP51 and FKBP52
observed during 3T3-L1 preadipocytes diﬀerentiation are
in agreement with their expression level in adipose tissue
that is high for FKBP51 and non-detectable for FKBP52
[130].
To uncover the functional importance of these IMM,
knockout mice were generated [125]. Fkbp51-deﬁcient mice
were initially observed to display no overt phenotype, but
these mice are less vulnerable to the detrimental eﬀects
of stress [131–133]. Interestingly, Fkbp51 knockout mice
showed reduced body weight compared to wild-type lit-
termates; however, upon exposure to chronic stress, these
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animals exhibited a signiﬁcant increase in body weight [133],
results that suggest that the process of adipogenesis may not
be impaired in the absence of FKBP51. A diﬀerential spatial
pattern of Fkbp51 gene induction in diﬀerent areas of the
brain depending on either diet or stress conditions has been
recently reported by Balsevich et al.. Inmice exposed to high-
fat diet, Fkbp51 is induced in the ventromedial hypothalamic
nuclei, in accordance with the hypothalamus being involved
in the control of energy balance [134]. In contrast, under con-
ditions of chronic stress, the expression of this IMM increases
in the hippocampus, area of the brain involved in the response
to stress [134]. Inasmuch as environmental stress is another
risk factor for the development of obesity [135], future
studies will uncover the role of FKBP51 in diﬀerent areas
of the brain, whether this IMM plays a role in the control of
appetite, energy balance and whether FKBP51 is implicated
in the relationship between control of energy, metabolic
homeostasis, and stress response. On the other hand,Fkbp52-
deﬁcient male mice display phenotypes related to partial
androgen insensitivity syndrome [136, 137]. Heterozygous
Fkbp52-deﬁcient mice show increased susceptibility to high
fat-diet-induced hyperglycemia and hyperinsulinemia that
correlates with reduced insulin clearance, hepatic steato-
sis, and glucocorticoid resistance [130]. However Fkbp51-
Fkbp52 doubled knock-out results in embryonic lethality
[125], indicating that these IMMs have some physiologic
functional redundancies that need to be uncovered by tissue-
speciﬁc conditional double knockout.
FKBP51 is present in mitochondria [138], and upon
oxidative stress the mitochondrial fraction of this IMM
rapidly translocates to the nucleus protecting cells from
apoptosis [138]. When 3T3-L1 preadipocytes are induced to
diﬀerentiate, FKBP51 also rapidly and transiently translo-
cates to the nucleus [33]. Adipogenesis is controlled by
many signaling pathways that coordinately modulate the
sequential activation of transcription factors required for cells
to diﬀerentiate [139]. We found that IBMX (3-isobutyl-1-
methylxanthine), a phosphodiesterase inhibitor that increases
intracellular cAMP, and to a lesser extent DEXA, are respon-
sible for the rapid relocalization of mitochondrial FKBP51 to
the nucleus [33]. Several reports have shown that the second
messenger cAMP is associated with immediate events of
adipogenesis by the classic PKA signaling pathway, as well
as by the non-classic pathway, the exchange proteins acti-
vated by cAMP (EPAC) that function as guanine nucleotide
exchange factor for the Ras-like small GTPases Rap1 and
Rap2 [140–143]. FKBP51 nuclear translocation depends on
PKA but not on EPAC pathway activation, demonstrating
another diﬀerential role of PKA and EPAC/Rap during
adipogenesis [33]. In the case of DEXA, it has been reported
that corticosterone possibly facilitates arachidonic acid (AA)
release and increased synthesis of prostacyclin, which in an
autocrine manner leads to cAMP generation required for the
diﬀerentiation of Ob1771 preadipocytes [18, 144]. The eﬀect
of corticosterone on AAmetabolism in Obl711 cells could be
contradictory considering the anti-inﬂammatory properties
of glucocorticoids upon inhibition of phospholipase A2;
however, there are studies that questioned this eﬀect [145,
146]. Further, based on the proadipogenic action of gluco-
corticoids, AA and prostacyclin signaling in adipose tissue
development [147], it is tempting to speculate that, in adipose
tissue, glucocorticoids may possibly mediate a diﬀerent bio-
logical response in AA pathway, possibility that needs to be
investigated. DEXA treatment also results in increased levels
of intracellular cAMP in other cell systems. For example,
glucocorticoid treatment of 3B4.15 T cells causes activation
of adenylate cyclase and a decrease in phosphodiesterase
activity [148], and in human airway epithelial cells DEXA
increases the beta2-adrenergic receptor-adenylate cyclase
system [149] leading to the increase in cAMP. It will be
relevant to investigate these possibilities in adipose cells, to
better understand corticosteroids actions both in adipogenesis
and the adipose tissue biology.
FKBP51 interacts with PKA-c𝛼 as shown by immuno-
precipitation assays, and when PKA signaling is blocked
dramatic changes in the electrophoretic pattern of migration
of FKBP51 are observed supporting the notion that FKBP51
is a PKA substrate [33]. By using NetPhosk 1.0, we found
that Serine 312 of FKBP51 is a candidate PKA phospho-
acceptor site. Serine 312 is in the TPR domain that confers to
the IMM the ability to bind Hsp90 through the EEVD motif
present in the extreme C terminus of the chaperone. FKBP51
localization in mitochondria depends on TPR integrity, since
FKBP51 TPR deﬁcient mutants are constitutively nuclear
[138]. Therefore, changes in phosphorylation in Serine 312
present in the TPR domain of FKBP51 may possibly regulate
its interaction with Hsp90 and consequently its subcellular
localization, possibility that is under current investigation.
Interestingly, when the interaction of FKBP51 with Hsp90
is disrupted by Hsp90 inhibitors such as radicicol, FKBP51
is no longer in mitochondria and concentrates in the nucleus
[138]. As mentioned already, geldanamycin and radicicol
inhibit 3T3- L1 preadipocytes diﬀerentiation [120–122].
Therefore, it is also possible that the Hsp90 inhibitors
not only aﬀect PPAR𝛾 , GR, and MR function but may
also alter the dynamic mitochondrial- nuclear shuttling of
FKBP51 at the onset of the diﬀerentiation process required
for adipogenesis to proceed.
However, during the last years several reports demonstrate
that FKBP51 functions are not circumscribed only to the
control of NRs. FKBP51 participates in the control of the
protein kinase Akt activity. The IMM is a scaﬀold protein for
the interaction between Akt and the PH domain leucine-rich
repeat protein phosphatase (PHLPP) that dephosphorylates
Serine 473 in Akt inhibiting the kinase activity [150].
It has been recently demonstrated that FKBP51 interacts
with overexpressed PPAR𝛾 in COS7 cells, and reporter
gene assays show that FKBP51 is a positive regulator of
this NR [87]. PPAR𝛾 like other NRs can be regulated
by changes in its phosphorylation status. MAPK ERK1/2
and JNK are able to phosphorylate PPAR𝛾 at serine 112
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reducing its transcriptional capacity [151–153]. Further,
inhibition of p38MAPK increases PPAR𝛾 expression and
its transcriptional activity [154]. GR is also a substrate
of p38MAPK, posttranslational modiﬁcation that increases
GR transcriptional capacity [155]. Taken together, MAPK-
dependent phosphorylation of PPAR𝛾 and GR has opposite
eﬀects on the transcriptional capacities of these NRs; PPAR𝛾
transactivation decreases while GR transactivation increases.
Stechschulte et al. showed that in mouse embryonic ﬁbrob-
lasts (MEFs) null for FKBP51 elevated Akt activity causes an
increased activation of p38MAPK leading to the phospho-
rylation of GR and PPAR𝛾 , posttranslational modiﬁcation
that induces the transcriptional activation of the former
and inhibition of the latter [87]. Further, they show that
knock-down of FKBP51 in 3T3- L1 preadipocytes makes
cells resistant to diﬀerentiation and MEFs from mice 51KO
have impaired diﬀerentiation [129]. The authors proposed a
model, in which FKBP51 restrains Akt activation by scaf-
folding PHLPP [87], favoring the inactive state of p38MAPK
that prevents PPAR𝛾 phosphorylation and keeps this NR in
a transcriptionally active state to induce the expression of
the adipogenic genes [129]. While the role of p38MAPK in
adipogenesis is rather controversial [154, 156–158], several
lines of evidence demonstrate that Akt is required for
proper adipogenesis. Akt is a key component of insulin
signaling and is required for PPAR𝛾 expression [139, 159].
Expression of constitutive active Akt induces spontaneous
diﬀerentiation of 3T3-L1 preadipocytes [160], and mice null
for Akt1 and Akt2 have impaired adipogenesis [159]. Akt
is responsible for phosphorylation and nuclear exclusion of
antiadipogenic factors such as the forkhead proteins FOXO-
1 [161] and FOXA-2 [162] and the transcription factor
GATA2 [163]. Therefore, proper activation of Akt is required
for normal adipogenesis and it can be speculated that Akt
inhibition by the FKBP51-PHLPP could have a negative
eﬀect on this process. In line with this possibility, Toneatto
et al. showed that knock-down of FKBP51 facilitates the
process of adipogenesis and its overexpression blocks 3T3-
L1 preadipocyte diﬀerentiation, based on the fact that this
IMM also restrains the adipogenic potential of GR [33], as
well as MR. It is possible that the discrepancies between
these two studies could result, in part, from diﬀerences in the
protocol of adipogenesis used in each case. More studies are
required to precise the role of FKBP51 during adipogenesis
and, in this way, shed light on this conundrum.
4.5. FKBP51 and the organization of the nuclear architecture
during adipogenesis. In a very simplistic description, as
depicted in Figure 2, the following compartments can be
distinguished in the interphase nucleus: 1- the nuclear lamina
that lies below the nuclear envelope ; 2- the nuclear matrix or
nucleoskeleton; 3- the chromosome territories that comprise
the volume of the nucleus in interphase occupied by each
chromosome; 4- the interchromatin domain; and 5- nuclear
bodies, including the nucleolus, spliceosomes or nuclear
speckles, paraspeckles, the Cajal bodies, the promyelocytic
bodies, and transcription factories, among others [164–
168]. The importance of the organization of the nuclear
architecture is highlighted by the evolutionary conservation
of chromosome territories [169], by the observation that
chromosome positions are heritable through the cell cycle
in mammalian cells [170] and interphase chromosomes, as
well as chromatin organization, undergo changes during
terminal diﬀerentiation [171–174]. Great body of evidence
shows that the genome has a dynamic 3D organization that
impinges in the transcriptional status of the cell. Chromatin
is not static and genes can be repositioned from repressive
to transcriptionally favorable nuclear compartments and vice
versa for their proper expression or repression [175–182]. It
is relevant to understand how the architecture of the nucleus
is delineated to uncover how the cell acquires and sustains
the pattern of gene expression require for the acquisition and
maintenance of the ﬁnal phenotype.
The nuclear lamina (NL) is a ﬁlamentous protein mesh-
work that lines the nucleoplasmic surface of the nuclear enve-
lope (NE) interacting with inner nuclear membrane proteins
and the nuclear pores (Figure 2) [183, 184], reviewed in [185,
186]. It consists of a polymeric assembly of lamins, members
of the type V intermediate ﬁlament proteins family [187] that
are the A-type (LA and LC) and the B-type lamins (LB1 and
LB2), respectively. LA and LC are derived from a single gene
by alternative splicing and are expressed only in diﬀerenti-
ated cells. On the other hand, LB1 and LB2 are expressed in
all cells throughout development [188]. The NL is thought
to provide a structural framework for the NE contributing
to the size, shape, and mechanical stability of the nucleus.
It also provides anchoring site for interphase chromosomes
at the nuclear periphery and plays important roles in DNA
replication and repair, RNA polymerase II transcription, and
the epigenetic control of chromatin remodeling [186, 189].
The functional importance of NL is demonstrated by the fact
that mutations in the lamin A/C or lamin-associated proteins
genes are responsible for a group of genetic diseases known
as laminopathies [186, 190] to which Dunnigan-type familial
partial lipodystrophy (FPLD) belongs [191–194], partial
lipodystrophy with mandibuloacral dysplasia (MAD) [195],
and lipoatrophy with diabetes, hepatic steatosis, hypertrophic
cardiomyopathy, and leukomelanodermic papules [196], dis-
eases that aﬀect the adipose tissue. In addition, laminopathies
such as Hutchinson-Gilford progeria and atypical Wermer´s
syndrome show generalized lipodystrophy, often combined
with insulin resistance [197–200].
In a recent study, analysis of mouse and humanmodel sys-
tems for adipogenesis showed fragmentation of the nuclear
lamina and subsequent loss of lamins A, C, B1, and emerin
at the nuclear rim, which coincides with reorganization
of nesprin-3/plectin/vimentin complex [201]. We have also
observed fragmentation of nuclear lamina at the early stages
of 3T3-L1 preadipocytes diﬀerentiation upon detection of
lamin B. Interestingly, fragmented lamin B not only colo-
calizes but also interacts with FKBP51 as well as PKA-c𝛼
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Figure 2: A) Schematic representation of the compartments of the nucleus in interphase NE: nuclear envelope, NPC: nuclear pore complex,
NL: nuclear lamina, NM: nuclear matrix, CTs: chromosome territories, MARs: matrix attachment regions that correspond to DNA sequences
that allow the interaction of chromatin to NM, and LADs: lamin attachment domains, corresponding to DNA sequences that allow the
interaction of chromatin to the nuclear lamina. B-C) 3T3-L1 preadipocytes grown on coverslips were incubated with DEXA in the absence
(B) or presence (C) of IBMX and subjected to indirect immunoﬂuorescence with anti-GR, anti-FKBP51, and secondary antibodies labeled
with Alexa 488 or Alexa 546, respectively, and images were analyzed by confocal microscopy. GR is detected in red, FKBP51 is detected
in green, and chromatin is stained by DAPI in blue. Inserts in each panel were magniﬁed. Observed in panel C is that DEXA plus IBMX
treatment caused enrichment of GR (red signal) in the nuclear area limited by the white dotted lines that correspond to NL.
[33]. Several phosphorylation sites are important in the NL
disassembly, including those for the cyclin B1-(CCNB1)-
CDC2 complex, PKC and PKA [202, 203]. Therefore, it is
possible that enrichment of FKBP51 and PKA-c𝛼 in the NL
may facilitate its reorganization by phosphorylation of lamins
during adipocyte diﬀerentiation.
During the last few years, several studies revealed a
dramatic and dynamic modulation of the chromatin land-
scape during the ﬁrst hours of adipocyte diﬀerentiation
[67, 68, 204–206]. These changes coincide with cooperative
binding of early adipogenic transcription factors, including
GR, to enhancers and promoters of many genes and high
level of chromatin relaxation [68, 205]. However, genes
such as PPAR𝛾 are not transcriptionally activated until later
time points of the adipogenic program, and it has been
proposed that the activation of additional factors and/or
signals is required for their later activation [68]. It can
be speculated that, in spite of chromatin relaxation and
the increased binding of transcription factors at the early
stages of adipogenesis, gene expression is kept controlled by
factors that restrain the transcriptional capacity of complexes
already bound to those sites. When adipogenesis is triggered
FKBP51 translocates to the nucleus; its interaction with GR
progressively increases rendering a GR less transcriptionally
active [33]. When cells are treated with DEXA in the
presence of IBMX GR has an increased presence in the
nuclear rim, area that corresponds to the NL (Figure 2, panel
C vs.B), a domain that is also transiently enriched in PKA-c𝛼
[33]. Therefore, we hypothesize that FKBP51 “sequesters”
GR in the nuclear rim to control its nuclear bioavailability as
shown for the control of AP-1 transcriptional activity upon
the sequestration of c-fos in the NL in an ERK1/2 dependent
manner [207, 208]. Interestingly, it has been shown that GR
interacts in vitro and in vivo with the catalytic subunit of
PKA in a ligand dependent manner and that GR transcription
depends on PKA signaling [209]. In this way PKA may play
a dual role in the regulation of GR, on one hand, modulating
positively GR transcriptional capacity [209] and, on the other
hand, restraining it by increasing the nuclear availability of
FKBP51, a known GR negative regulator [104] that possibly
modulates its nuclear distribution in diﬀerent compartments.
It is possible that the presence of FKBP51 in the nucleus
may be critical for the control not only of GR but also for
MR at the onset of adipogenesis. Future studies will possibly
demonstrate the existence of other transcription factors that
do not belong to the NR family that need to be repressed or
even activated by nuclear FKBP51 to keep their transcription
under control, at a step of the adipogenic program in which
high level of chromatin remodeling takes place.
5. Final Remarks
Undoubtedly during the last decade, great progress has been
accomplished in the understanding of the complex biology
of the adipose tissue, the pathophysiology of obesity and
its participation in the metabolic syndrome. However, many
aspects of the physiology of the adipocyte including how
corticosteroids modulate its biological responses need to
be explored further in depth. Uncovering at the molecular
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level on how diﬀerent fat depots respond to the gluco- and
mineralocorticoid stimuli and how corticosteroid receptors,
their chaperones and cochaperones, control adipocyte dif-
ferentiation will not only enrich our basic knowledge but
also will be key for the design of new therapeutic strategies
for the treatment of obesity, lipodystrophies, and metabolic
problems associated with these pathologies.
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